Literature DB >> 25764576

Reversing Halt, FDA reauthorizes sale of ponatinib.

Andrew J Roth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25764576

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN： 1088-0224            Impact factor:   2.229


× No keyword cloud information.
  2 in total

1.  Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Authors:  M S Zabriskie; C A Eide; D Yan; N A Vellore; A D Pomicter; S L Savage; B J Druker; M W Deininger; T O'Hare
Journal:  Leukemia       Date:  2015-11-19       Impact factor: 11.528

2.  Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.

Authors:  Haoyu Li; Yongfeng Wang; Zhenghu Chen; Jiaxiong Lu; Jessie Pan; Yang Yu; Yanling Zhao; Huiyuan Zhang; Ting Hu; Qing Liu; Jianhua Yang
Journal:  Oncotarget       Date:  2017-01-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.